• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Sionna Therapeutics Inc.

    4/29/25 7:31:12 AM ET
    $SION
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SION alert in real time by email
    DEFA14A 1 d946596ddefa14a.htm DEFA14A DEFA14A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material under §240.14a-12

    SIONNA THERAPEUTICS, INC.

    (Name of Registrant as Specified in Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required.

     

    ☐

    Fee paid previously with preliminary materials.

     

    ☐

    Fee computed on table below in exhibit required by Item 25(b) Exchange Act Rules 14a-6(i)(14) and 0-11.

     

     
     


    LOGO

    Your Vote Counts! SIONNA THERAPEUTICS, INC. 2025 Annual Meeting Vote by June 11, 2025 11:59 PM ET SIONNA THERAPEUTICS, INC. 21 HICKORY DRIVE, SUITE 500 WALTHAM, MA 02451 V72401-P31556 You invested in SIONNA THERAPEUTICS, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 12, 2025. Get informed before you vote View the Notice and Proxy Statement and Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 29, 2025. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Vote Virtually at the Meeting* Point your camera here and June 12, 2025 10:00 AM EDT vote without entering a control number Virtually at: www.virtualshareholdermeeting.com/SION2025 *Please check the meeting materials for any special requirements for meeting attendance.


    LOGO

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote on these important matters. Board Voting Items Recommends 1. To elect three class I directors to serve until our 2028 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal. Nominees: For 01) Joshua Resnick, M.D., M.B.A. 02) Bruce Booth, D.Phil. 03) Lucian Iancovici, M.D. 2. To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the For fiscal year ending December 31, 2025. NOTE: In their discretion, the proxies are authorized to vote upon such other business as may properly come before the meeting or any continuation, adjournment or postponement thereof. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V72402-P31556

    Get the next $SION alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SION

    DatePrice TargetRatingAnalyst
    3/4/2025Buy
    TD Cowen
    3/4/2025$32.00Buy
    Stifel
    3/4/2025$45.00Buy
    Guggenheim
    More analyst ratings

    $SION
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TD Cowen initiated coverage on Sionna Therapeutics

      TD Cowen initiated coverage of Sionna Therapeutics with a rating of Buy

      3/4/25 8:27:05 AM ET
      $SION
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on Sionna Therapeutics with a new price target

      Stifel initiated coverage of Sionna Therapeutics with a rating of Buy and set a new price target of $32.00

      3/4/25 7:43:40 AM ET
      $SION
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Sionna Therapeutics with a new price target

      Guggenheim initiated coverage of Sionna Therapeutics with a rating of Buy and set a new price target of $45.00

      3/4/25 7:43:20 AM ET
      $SION
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SION
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Fitzpatrick Jennifer

      3 - Sionna Therapeutics, Inc. (0002036042) (Issuer)

      4/1/25 4:05:16 PM ET
      $SION
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Tpg Gp A, Llc converted options into 4,875,547 shares and bought $20,250,000 worth of shares (1,125,000 units at $18.00) (SEC Form 4)

      4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)

      2/12/25 5:21:33 PM ET
      $SION
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SION
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sionna Therapeutics Reports First Quarter 2025 Financial Results

      Phase 1 dosing completed for NBD1 stabilizers SION-719 & SION-451; both compounds continue to be generally well tolerated Phase 1 topline data anticipated this quarter On track to initiate Phase 2a proof-of-concept trial and at least one dual combination MAD trial in the second half of 2025; topline data for both anticipated in mid-2026 Strong cash position following completed upsized IPO, with approximately $354.7 million in cash and cash equivalents, expected to fund operations into 2028 WALTHAM, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for c

      5/12/25 7:00:00 AM ET
      $SION
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sionna Therapeutics to Present at The Citizens Life Sciences Conference 2025

      WALTHAM, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will present at The Citizens Life Sciences Conference on Wednesday, May 7, 2025 at 12:30 p.m. ET. A live webcast of the presentation will be available the day of the event on the "Events" page within the Investors section of Sionna's website at https://investors.sionnatx.com/. A replay will be available for 90

      4/30/25 7:00:00 AM ET
      $SION
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

      Phase 1 MAD dosing completed for SION-451 and final MAD cohort of SION-719 planned; Interim data in healthy volunteers show potential to provide clinically meaningful benefit to CF patients. Topline data anticipated in first half of 2025 On track to initiate NBD1 Phase 2a proof-of-concept trial in combination with SOC in CF patients and combination MAD trials of an NBD1 stabilizer with a complementary modulator in healthy volunteers in the second half of 2025, with topline data for both anticipated in mid-2026 Completed upsized IPO with gross proceeds of approximately $219 million, extending runway into 2028 WALTHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, I

      3/20/25 7:00:00 AM ET
      $SION
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SION
    SEC Filings

    See more
    • SEC Form 10-Q filed by Sionna Therapeutics Inc.

      10-Q - Sionna Therapeutics, Inc. (0002036042) (Filer)

      5/12/25 7:31:04 AM ET
      $SION
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sionna Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - Sionna Therapeutics, Inc. (0002036042) (Filer)

      5/12/25 7:12:56 AM ET
      $SION
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Sionna Therapeutics Inc.

      DEFA14A - Sionna Therapeutics, Inc. (0002036042) (Filer)

      4/29/25 7:31:12 AM ET
      $SION
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SION
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Tpg Gp A, Llc converted options into 4,875,547 shares and bought $20,250,000 worth of shares (1,125,000 units at $18.00) (SEC Form 4)

      4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)

      2/12/25 5:21:33 PM ET
      $SION
      Biotechnology: Pharmaceutical Preparations
      Health Care